SK Bioscience Strengthens Global R&D Network... Collaborates with Doherty Institute

SK Bioscience is continuously expanding its global vaccine research and development (R&D) network.

Ahn Jae-yong, CEO of SK Bioscience (left), and Sharon Lewin, Director of the Peter Doherty Institute for Infection and Immunity in Australia, are posing for a commemorative photo at the signing ceremony of the research cooperation agreement.
[Photo by SK Bioscience]

On the 27th, SK Bioscience announced that it has signed a research collaboration agreement with The Peter Doherty Institute for Infection and Immunity in Australia for global influenza prevention and response. The Doherty Institute, affiliated with the University of Melbourne, is an infectious disease research institution in Australia and serves as a World Health Organization (WHO) Collaborating Centre for Influenza as well as one of the world's top three suppliers of influenza virus strains.

The signing ceremony held at SK Bioscience’s headquarters in Pangyo, Seongnam-si, Gyeonggi-do, was attended by Sharon Lewin, Director of the Doherty Institute and Head of the Department of Infectious Diseases at the University of Melbourne; Kanta Subbarao, Director of the Doherty Institute and WHO Collaborating Centre for Influenza Research and Surveillance; Ian Barr, Deputy Director of the Doherty Institute and WHO Collaborating Centre for Influenza Research and Surveillance; and from SK Bioscience, President Jae-yong Ahn and Global R&BD Head Hoon Kim. Both institutions agreed to closely collaborate to advance influenza vaccine research and development by focusing on ▲basic research of new influenza vaccine platforms and ▲monitoring the latest global influenza research technologies and industry trends.

Through this collaboration, SK Bioscience plans to strengthen influenza prevention and response systems, secure competitiveness in the global influenza market, and lead the advancement of R&D. According to the global market research firm Fortune Business Insight, the global influenza vaccine market size is expected to grow from $7.54 billion (approximately 10 trillion KRW) in 2022 to $13.58 billion (approximately 17.7355 trillion KRW) by 2029, with an average annual growth rate of 8.8%.

Director Lewin of the Doherty Institute said, “Participating in this influenza vaccine development collaboration project is a significant achievement in our efforts to fight diseases and promote public health. Through cooperation with SK Bioscience, we aim to foster innovation, share knowledge, respond to global crises, and continuously expand our impact.”

SK Bioscience President Jae-yong Ahn also stated, “We look forward to the synergy created by our expertise in developing the world’s first quadrivalent cell-based influenza vaccine and the Doherty Institute’s leading infrastructure in global infectious disease research. We will strengthen existing collaborations with various global institutions and continue to expand cooperation into new areas to lead the creation of a global infectious disease prevention ecosystem.”

This content was produced with the assistance of AI translation services.